item management s discussion and analysis of financial condition and results of operation 
results of operation the following table sets forth  for the three most recent fiscal years  the percentage relationship to net sales of principal items in the company s consolidated statements of operations fiscal year ended june  net sales cost of goods sold gross profit selling expenses general and administrative expenses research and development expenses total operating expenses loss from operations other income loss before minority interest and income taxes minority interest in net income loss of consolidated subsidiaries loss before income taxes income tax provision benefit net loss the following discussion and analysis provides information which the company s management believes is relevant to an assessment and understanding of the company s results of operations and financial condition 
this discussion should be read in conjunction with the consolidated financial statements and notes thereto appearing elsewhere herein 
all of the company s sales to date have been derived from the sale of medical device products  which include manufacture and distribution of ultrasonic medical device products  and laboratory and scientific products  which include ultrasonic equipment for scientific and laboratory purposes  and ductless fume enclosures for filtration of gaseous emissions in laboratories and hospitals 
fiscal years ended june  and net sales net sales increased  to  in fiscal from  in fiscal this difference in net sales is principally due to an increase in laboratory and scientific products sales of  to  in fiscal from  in fiscal this difference in net sales is also due to an increase in sales of medical device products of  to  in fiscal from  in fiscal the increase in sales of medical device products is principally due to an increase in sales of diagnostic medical device products 
the increase in sales of diagnostic medical device products was attributable to several new customers  an increase in customer demand for several new products and increased repair capability 
the increase in sales of laboratory and scientific products is due to a  increase in labcaire products sales  an increase in ultrasonic product sales and an increase in ductless fume enclosure product sales  partially offset by a decrease in sales of wet scrubber products 
the company has intentionally limited the opportunities it pursues for wet scrubber products 
the increase in labcaire sales of  is due to shipments of its new isis endoscope cleaning system and the strengthening of the english pound versus the us dollar  which accounted for approximately  of the sales increase 
the increase in ultrasonic product sales and ductless fume enclosure product sales is due to an increase in customer demand for several products including the new s digital sonicator and is not attributable to a single customer  distributor or any other specific factor 
export sales from the united states are remitted in us dollars and export sales for labcaire are remitted in english pounds 
ukhifu sales are remitted in english pounds and misonix  ltd 
sales to date have been remitted in english pounds and euros 
to the extent that the company s revenues are generated in english pounds  its operating results were translated for reporting purposes into us dollars using weighted average rates of and for the years ended june  and  respectively 
a strengthening of the english pound and euro  in relation to the us dollar  will have the effect of increasing recorded revenues and profits  while a weakening of the english pound and euro will have the opposite effect 
since the company s operations in england generally set prices and bids for contracts in english pounds  a strengthening of the english pound  while increasing the value of its uk assets  might place the company at a pricing disadvantage in bidding for work from manufacturers based overseas 
the company collects its receivables predominately in the currency of the country the subsidiary resides in 
the company has not engaged in foreign currency hedging transactions  which include forward exchange agreements 
see item a 
quantitative and qualitative disclosures about market risk the company s revenues are generated from various geographic regions 
the following is an analysis of net sales by geographic region year ended june  united states united kingdom europe asia canada and mexico middle east other summarized financial information for each of the segments for the years ended june  and are as follows for the year ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income loss from operations for the year ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income loss from operations net sales for the three months ended june  were  compared to  for the three months ended june  the increase of  is due to an increase in laboratory product sales of  primarily due to an increase in labcaire and ultrasonic products sales 
therapeutic medical device products sales decreased approximately  and diagnostic medical device products sales increased approximately  the increase in diagnostic medical device products sales was primarily attributable to the sale of equipment to a probe repair lab in europe and fees earned for training their personnel 
summarized financial information for each of the segments for the three months ended june  and are as follows for the three months ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income loss from operations for the three months ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income loss from operations gross profit gross profit increased to in fiscal from in fiscal gross profit for medical device products increased to in fiscal from in fiscal gross profit for therapeutic medical device products was positively impacted by a favorable product mix due to increased sales of the sonastar ultrasonic surgical aspirator product in the united states and foreign markets and increased sales of ultrasonic assisted liposuction products 
sales of the company s autosonix products to uss which have lower gross profits  decreased in fiscal as percentage of total sales 
the fiscal period also benefited from a favorable mix of diagnostic medical device products sales 
gross profit for laboratory and scientific products decreased to in fiscal from in fiscal due to lower margins at labcaire due to higher costs related to the isis units shipped 
gross profit for the three months ended june  increased to from in the three months ended june  gross margins for medical device products sales increased to in the period from in the period 
the increase was due to a favorable product mix in both therapeutic and diagnostic product sales 
gross profit for laboratory and scientific products decreased to in the period from in the period 
the decrease in gross profit was primarily due to lower margins in labcaire due to higher costs related to the isis units shipped and lower margins for fume enclosure product sales due to unfavorable product mix 
selling expenses selling expenses increased  to  of net sales in fiscal from  of net sales in fiscal laboratory and scientific products selling expenses increased approximately  predominately due to increased selling and service expenses at labcaire related to higher sales and the impact of the stronger english pound of approximately  selling expenses for therapeutic medical device products increased approximately  principally due to new hires in medical sales management and increased expenses in europe related to the company s hifu products  partially offset by reduced expenses related to trade shows and exhibitions 
selling expenses related to diagnostic medical device products decreased approximately  principally due to decreased costs associated with consignment equipment 
selling expenses for the three months ended june  increased  to  of net sales from  of net sales in the three months ended june  selling expenses related to therapeutic medical device products sales increased approximately  principally due to increased staffing 
laboratory and scientific products selling expenses decreased approximately  principally due to lower costs associated with demo equipment 
general and administrative expenses total corporate and unallocated expenses increased  in fiscal to  from  in fiscal general and administrative expenses increased in fiscal  principally due to increased employee related expense of approximately  increased depreciation expense  increased recruiting fees of approximately  related to adding personnel to the therapeutic medical group  increased bank fees and higher consulting fees  which were partially offset by decreased insurance expense and decreased bad debt expense 
the higher consulting fees include approximately  related to the implementation of section a of the sarbanes oxley act of section a 
the company entered into revolving credit facility with wells fargo bank on december  and bank fees in the period are twelve months compared to six months in fiscal general and administrative expenses for the three months ended june  increased  to  from  for the three months ended june  the increase was due to increased employee related expense of approximately  consulting costs of approximately  related to the implementation of section a and approximately  of higher costs related to the company s hifu business in europe 
the increased salary expense includes bonus expense at sonora which exceeded its profit objectives for fiscal research and development expenses research and development expenses decreased  to  in fiscal from  in fiscal research and development expenses for medical device products increased approximately  research and development expenses for diagnostic medical device products increased approximately  related to developing new products and services which were introduced during the current fiscal year 
research and development expenses for therapeutic medical devices decreased approximately  the decrease is primarily due to decreased salary and consulting fees of  which were partially offset by a milestone charge of  from focus related to the hifu kidney cancer research project 
laboratory and scientific products research and development expenses decreased approximately  due to reduced efforts on the labcaire isis product which was introduced and launched in the fourth quarter of fiscal and completing the s digital sonicator product introduced during the first quarter of fiscal research and development expense for the three months ended june  decreased  to  from  in the three months ended june  in the three months ended june   approximately  of medical device products development expense related to improvements to existing therapeutic medical device products was deferred which was partially offset by increased expenses related to diagnostic medical products 
research and development expenses for laboratory and scientific products decreased in the three months ended june  due to reduced efforts related to the labcaire isis product and the completion of the s digital sonicator product 
other income other income decreased  in fiscal to  from  in fiscal the fiscal year included foreign currency exchange gains of approximately  which were primarily attributable to an exchange gain resulting from the payment of an intercompany loan denominated in british pounds by labcaire to the company 
royalty and license fee income from uss decreased approximately  in fiscal due to decreased sales by uss of the company s autosonix product 
in addition  royalty expense in fiscal increased approximately  which increase was attributable to licensed probe repair technology  the sale of acoustic power tanks and increased sales of lysonix medical device products 
the decrease in other income in fiscal was partially offset by  from the realization of a previously impaired secured cumulative convertible debenture from focus during the second quarter of fiscal which was used to reduce a milestone payment to focus and reduced interest expense of  the fiscal period included a loss of  from the sale of equipment 
other income expense decreased  to  for the three months ended june  from  for the three months ended june  the decrease is due to decreased foreign currency exchange gains partially offset by decreased interest expense and decreased royalty expense 
the three months ended june  included an exchange gain of approximately  resulting from the payment of a loan denominated in british pounds by labcaire to the company 
income taxes in fiscal the company increased the valuation allowance related to deferred tax assets by approximately  which increased income tax expense to an effective tax rate of 
in its assessment of whether it is more likely than not that some portion or all the deferred tax assets will be realized  management increased the valuation allowance for the deferred tax benefit related to us federal loss carryforwards and unused tax credit carryforwards which are available to offset future taxable income 
the effective tax rate in fiscal of was favorably impacted by an additional  of research and experimentation credits provided by the enactment of the tax relief and healthcare act of hr which retroactively extended the tax credit for research and experimentation expenditures 
the fiscal effective income tax rate differs from the statutory rate due to the impact of permanent differences related to sfasr stock based compensation and non deductible entertainment expenses on taxable income 
in addition  the  of income from the realization of a previously written off debt from focus was not tax effected because the company did not record an income tax benefit when the debt was originally written off 
fiscal years ended june  and net sales 
net sales of the company s medical device products and laboratory and scientific products increased  to  in fiscal from  in fiscal this difference in net sales is due to an increase in sales of medical device products of  to  in fiscal from  in fiscal this difference in net sales is also due to an increase in laboratory and scientific product sales of  to  in fiscal from  in fiscal the increase in sales of medical device products is due to an increase in sales of therapeutic medical device products of  plus an increase of  in sale of diagnostic medical device products 
the increase in sales of therapeutic medical device products was primarily attributable to the increased units of the sonablate in fiscal  the company sold sonablate units compared to unit in fiscal additionally  the company acquired of ukhifu at the end of the third quarter of fiscal and the company had the benefit of the fee per use revenue of  for the entire fiscal year 
the increase in sales of diagnostic medical device products was not attributable to a single customer  distributor or any other specific factor but an increase in customer demand for several products 
the increase in sales of laboratory and scientific products is primarily due to a  increase in labcaire products  partially offset by a  decrease in sales of wet scrubber products 
the company is being very selective in the opportunities it pursues for wet scrubber products 
the increase in labcaire sales of  is due to an increase in guardian endoscope products and services of  and the strengthening of the british pound versus the us dollar of approximately  the increase in ductless fume enclosure product sales is due to an increase in customer demand for several products and not attributable to a single customer  distributor or any other specific factor 
export sales from the united states are remitted in us dollars and export sales for labcaire are remitted in british pounds 
ukhifu sales are remitted in british pounds and misonix  ltd 
sales to date have been remitted in euros 
to the extent that the company s revenues are generated in british pounds  its operating results were translated for reporting purposes into us dollars using weighted average rates of and for the years ended june  and  respectively 
to the extent that the company s revenues are generated in euros  its operating results were translated for reporting purposes into u 
s dollars using a weighted average rate of for the year ended june  a strengthening of the british pound and euro  in relation to the us dollar  will have the effect of increasing recorded revenues and profits  while a weakening of the british pound and euro will have the opposite effect 
since the company s operations in england generally set prices and bids for contracts in british pounds  a strengthening of the british pound  while increasing the value of its uk assets  might place the company at a pricing disadvantage in bidding for work from manufacturers based overseas 
the company collects its receivables predominately in the currency of the country the subsidiary resides in 
the company has not engaged in foreign currency hedging transactions  which include forward exchange agreements 
the company s revenues are generated from various geographic regions 
the following is an analysis of net sales by geographic region united states united kingdom europe asia canada and mexico middle east other summarized financial information for each of the segments for the years ended june  and are as follows for the year ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income loss from operations for the year ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income from operations net sales for the three months ended june  were  compared to  for the three months ended june  this increase of  for the three months ended june  is due to an increase in sales of medical device products of  and an increase in laboratory and scientific products sales of  the increase in sales of medical device products was due to an increase in sales of diagnostic medical devices products of  and an increase of  in sales of therapeutic medical device products 
the increase in sales of diagnostic medical device products was not attributable to a single customer  distributor or any other specific factor 
the increase in sales of therapeutic medical device products was mostly attributable to an increase in sales of the company s neuroaspirator of approximately  an increase in sales of the company s lithotripter product of approximately  an increase in sales of the company s ultrasonic assisted liposuction product of approximately  and an increase in sales of the company s sonablate product of approximately  the increase in laboratory and scientific products sales is due to an increase in labcaire products sales of  the strengthening of the english pound versus the us dollar of  an increase in ultrasonic laboratory products sales of  and an increase in ductless fume enclosure product sales of  partially offset by a decrease in wet scrubber sales of  summarized financial information for each of the segments for the three months ended june  and are as follows for the three months ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income loss from operations for the three months ended june  medical devices laboratory and scientific products corporate and unallocated total net sales cost of goods sold gross profit selling expenses research and development general and administrative total operating expenses income from operations gross profit 
gross profit increased to in fiscal from in fiscal gross profit for medical device products increased to in fiscal from in fiscal gross profit for laboratory and scientific products increased to in fiscal from in fiscal gross profit for medical device products was impacted by a favorable order sales mix of therapeutic medical device products  partially offset by lower gross margins on sales to uss and an unfavorable mix of diagnostic medical device products sales 
the increase in gross profit for laboratory and scientific products was due to higher gross profit for wet scrubbers  fume enclosure products and labcaire products 
gross profit increased to of sales in the three months ended june  from of sales in the three months ended june  gross profit for laboratory and scientific products increased to of sales in the three months ended june  from in the three months ended june  gross profit for medical device products increased from of sales in the three months ended june  to of sales in the three months ended june  the increase in gross profit for laboratory and scientific products was predominately due to increased service revenue at labcaire 
the increase in gross profit for medical device products was predominately due to a favorable order mix for sales of therapeutic medical device products 
the company manufactures and sells both medical device products and laboratory and scientific products with a wide range of product costs and gross margin dollars as a percentage of revenues 
selling expenses 
selling expenses increased  or to  of net sales in fiscal from  of net sales in fiscal medical device products selling expenses increased  due both to additional sales and marketing efforts for therapeutic medical device products 
laboratory and scientific products selling expenses decreased  selling expenses decreased  to  of net sales in the three months ended june  from  of net sales in the three months ended june  medical device products selling expenses decreased  due to reduced sales and marketing efforts for therapeutic medical device products 
laboratory and scientific products selling expenses increased  predominantly due to an increase in sales and marketing efforts for labcaire s isis product 
general and administrative expenses 
total corporate and unallocated expenses decreased  to  in fiscal year from  in fiscal the decrease is predominantly due to reduced stock based compensation expense of approximately  related to the adoption of statement of financial accounting standards sfas no 
r  and a reduction in corporate general and administrative expenses relating to corporate insurance  legal fees and other accrued corporate expenses 
total general and administrative expenses decreased  to  in the three months ended june  from  in the three months ended june  the decrease is predominantly due to a decrease in legal fees spent at sonora and other accrued corporate expenses 
research and development expenses 
research and development expenses decreased  to  in fiscal from  in fiscal research and development expenses related to medical device products decreased  and research and development expenses related to laboratory and scientific products deceased  research and development expenses related to medical device products decreased predominately due to reduced efforts relating to the digital upgrade project for therapeutic medical device products  partially offset by efforts expended on the new laboratory and scientific digital sonicator product 
the decrease in research and development expense relating to laboratory and scientific products is due to the reduced efforts on the labcaire isis product which was introduced and launched during fiscal and the reduced efforts for wet scrubber products 
the company is not expanding efforts for research and development on wet scrubber products 
research and development expense decreased  for the three months ended june  to  from  for the three months ended june  research and development expense related to medical device products decreased  and research and development expense related to laboratory scientific products decreased  research and development expense related to medical device products decreased predominately due to reduced efforts relating to the digital project upgrade for therapeutic medical device products  partially offset by efforts expanded on the new laboratory and scientific digital sonicator product 
the decrease in laboratory and scientific products research and development expenses is due to reduced effort on the labcaire isis product  which was introduced and launched during fiscal  and the reduced research and development efforts for wet scrubber products 
other income expense 
other income was  in fiscal as compared to  in fiscal the decrease of  for the fiscal year was primarily due to an increase in interest expense of  partially offset by increased foreign currency exchange gains of  and increased royalty income of  the increase in interest expense is principally attributable to increased borrowings in the united states 
income taxes 
the effective tax rate is for the fiscal year ended june  as compared to an effective tax rate of for the fiscal year ended june  the fiscal year tax rate includes the release of the valuation allowance of  related to bad debt expenses which was partially offset by adjustments to state tax rates and the impact of lower foreign tax rates 
critical accounting policies general financial reporting release no 
 which was released by the sec in december  requires all companies to include a discussion of critical accounting policies or methods used in the preparation of the financial statements 
note of the notes to consolidated financial statements included in this annual report includes a summary of the company s significant accounting policies and methods used in the preparation of its financial statements 
the company s discussion and analysis of its financial condition and results of operations are based upon the company s financial statements  which have been prepared in accordance with accounting principles generally accepted in the united states 
the preparation of these financial statements requires the company to make estimates and judgments that affect the reported amounts of assets  liabilities  revenues and expenses 
on an on going basis  management evaluates its estimates and judgments  including those related to bad debts  inventories  goodwill  property  plant and equipment and income taxes 
management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances  the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources 
actual results may differ from these estimates under different assumptions or conditions 
the company considers certain accounting policies related to accounts receivable  inventories  property  plant and equipment  revenue recognition  goodwill  income taxes and stock based compensation to be critical policies due to the estimation process involved in each 
accounts receivable accounts receivable  principally trade  are generally due within to days and are stated at amounts due from customers  net of an allowance for doubtful accounts 
the company performs ongoing credit evaluations and adjusts credit limits based upon payment history and the customer s current credit worthiness  as determined by a review of their current credit information 
the company continuously monitors aging reports  collections and payments from customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified 
while such credit losses have historically been within expectations and the provisions established  the company cannot guarantee the same credit loss rates will be experienced in the future 
the company writes off accounts receivable when they become uncollectible 
inventories inventories are stated at the lower of cost first in  first out or market and consist of raw materials  work in process and finished goods 
management evaluates the need to record adjustments for impairments of inventory on a quarterly basis 
the company s policy is to assess the valuation of all inventories  including raw materials  work in process and finished goods 
inventory items used for demonstration purposes  rentals or on consignment are classified in property  plant and equipment 
property  plant and equipment property  plant and equipment are recorded at cost 
the company capitalizes items in excess of  minor replacements and maintenance and repair expenses are charged to expense as incurred 
depreciation of property and equipment is provided using the straight line method over estimated useful lives ranging from to years 
depreciation of the labcaire building was provided using the straight line method over the estimated useful life of years 
leasehold improvements are amortized over the life of the lease or the useful life of the related asset  whichever is shorter 
the company s policy is to periodically evaluate the appropriateness of the lives assigned to property  plant and equipment and to make adjustments if necessary 
inventory items included in property  plant and equipment are depreciated using the straight line method over estimated useful lives of to years 
labcaire sold its owned building in the united kingdom in june in a sale and leaseback agreement with tesco 
tesco intends to utilize the property to expand its operations which will require labcaire to relocate to another facility upon tesco s receiving permission to expand from the local authorities 
labcaire sold the building for million and recorded a deferred gain of million which will be amortized over the year lease period 
additionally  upon tesco s receiving permission to expand its facilities which is expected in the next to years  tesco will cancel the lease 
upon labcaire vacating the premises  tesco will pay labcaire an additional million under the agreement 
revenue recognition the company records revenue upon shipment for products shipped fob shipping point 
products shipped fob destination points are recorded as revenue when received at the point of destination 
shipments under agreements with distributors are not subject to return  and payment for these shipments is not contingent on sales by the distributor 
the company recognizes revenue on shipments to distributors in the same manner as with other customers 
fees from exclusive license agreements are recognized ratably over the terms of the respective agreements 
service contract and royalty income are recognized when earned 
goodwill goodwill represents the excess of the purchase price over the fair value of the net assets acquired in connection with the company s acquisitions of the common stock of labcaire  of the common stock of sonora and the acquisitions of assets of fibra sonics  sonic technologies and cramar and an equity interest in ukhifu 
in july  the financial accounting standards board fasb issued sfas nos 
sfas and sfas  business combinations and goodwill and other intangible assets  respectively 
sfas replaced accounting principles board apb opinion business combinations and requires the use of the purchase method for all business combinations initiated after june  sfas requires goodwill and intangible assets with indefinite useful lives to no longer be amortized  but instead be tested for impairment at least annually and whenever events or circumstances occur that indicate goodwill might be impaired 
with the adoption of sfas  as of july   the company reassessed the useful lives and residual values of all acquired intangible assets to make any necessary amortization period adjustments 
based on that assessment  only goodwill was determined to have an indefinite useful life and no adjustments were made to the amortization period or residual values of other intangible assets 
the company completed its annual goodwill impairment tests for fiscal and in the respective fourth quarter 
there were no indicators that goodwill recorded was impaired 
income taxes income taxes are accounted for in accordance with sfas no 
 accounting for income taxes sfas no 

under this method  deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards 
deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled 
the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date 
stock based compensation prior to july   the company accounted for stock option plans sfas no 
as permitted under this standard  compensation cost was recognized using the intrinsic value method described in apb no 
apb 
effective july   the company adopted the fair value recognition provisions of sfas no 
r revised  share based payment sfas no 
r and sec staff accounting bulletin no 
using the modified prospective transition method  therefore  prior periods have not been restated 
see note of the company s consolidated financial statements for additional information regarding stock based compensation 
liquidity and capital resources working capital at june  and june  was  and  respectively 
for the twelve months ended june   cash provided by operations totaled  a major source of cash from operations was the receipt of  held by the bank of america boa to secure a standby letter of credit after the company terminated its credit agreement with boa 
this amount was included in prepaid expenses and other current assets at june  the major use of cash from operations was related to increased accounts receivable and inventories of approximately  and  respectively  during the year ended june  the increases were attributable to the company s labcaire subsidiary 
for the fiscal year  cash used in investing activities totaled  primarily consisting of the purchase of property  plant and equipment during the regular course of business and the purchase of shares of the common stock of sonora increasing the company s ownership to 
for the fiscal year  cash used in financing activities was  primarily consisting of net proceeds from short term borrowings of  offset by principal payments of capital lease obligations of approximately  revolving credit facilities on december   the company and its subsidiaries  sonora and hearing innovations the company  sonora and hearing innovations collectively referred to as the borrowers and wells fargo bank entered into a i credit and security agreement and a ii credit and security agreement export import subfacility collectively referred to as the credit agreements 
the aggregate credit limit under the credit agreements is  consisting of a revolving facility in the amount of up to  up to  of the revolving facility is available under the export import agreement as a subfacility for export import working capital financing 
all credit facilities under the credit agreements mature on december  payment of amounts outstanding under the credit agreements may be accelerated upon the occurrence of an event of default as defined in the credit agreements 
all loans and advances under the credit agreements are secured by a first priority security interest in all of the borrowers accounts receivable  letter of credit rights  and all other business assets 
the borrowers have the right to terminate or reduce the credit facility prior to december  by paying a fee based on the aggregate credit limit or reduction  as the case may be as follows i during year one of the credit agreements   ii during year two of the credit agreements   and iii during year three of the credit agreements  
the credit agreements  as amended  contain financial covenants requiring that the borrowers i on a consolidated basis not have a net loss as defined in the credit agreements of more than a  for the fiscal quarter ended march  and b  for the fiscal quarter ending june  and ii not incur or contract to incur capital expenditures as defined in the credit agreements of more than  in the aggregate in any fiscal year or more than  in any one transaction 
at june   the borrowers were not in compliance with two of the covenants under the credit agreements 
wells fargo bank has given the company a waiver of such non compliance 
the available amount under the credit agreements is the lesser of  or the amount calculated under the borrowing base as defined in the credit agreements 
the borrowers must maintain a minimum outstanding amount of  under the credit agreements at all times and pay a fee equal to the interest rate set forth on any such shortfall 
interest on amounts borrowed under the credit agreements is payable at wells fargo s prime rate of interest plus per annum floating  payable monthly in arrears 
the default rate of interest is higher than the rate otherwise payable 
a fee of per annum on the unused amount as defined in the credit agreements is payable monthly in arrears 
at june   the balance outstanding under the credit agreement was  and an additional  was available under this line of credit 
labcaire has a debt purchase agreement with lloyds tsb commercial finance 
the amount of this facility bears interest at the bank s base rate at june  plus and fluctuates based upon the outstanding united kingdom and european receivables 
the agreement expires september  the agreement covers all united kingdom and european sales 
at june   the balance outstanding under this credit facility was  and labcaire was in compliance with all financial covenants 
commitments the company has commitments under a revolving credit facility  note payable and capital and operating leases that will be funded from operating sources 
at june   the company s contractual cash obligations and commitments relating to the revolving credit facilities  note payable and capital and operating leases are as follows commitment less than year years years after years total revolving credit facilities note payable capital leases operating leases off balance sheet arrangements the company has no off balance sheet arrangements that have or are reasonably likely to have a current or future effect on the company s financial condition  changes in financial condition  revenues or expenses  results of operations  liquidity  capital expenditures or capital resources that is material to the company 
other the company believes that its existing capital resources will enable it to maintain its current and planned operations for at least months from the date hereof 
in the opinion of management  inflation has not had a material effect on the operations of the company 
item a 
quantitative and qualitative disclosures about market risk market risk the principal market risks ie  the risk of loss arising from adverse changes in market rates and prices to which the company is exposed are interest rates on short term investments and foreign exchange rates  which generate translation gains and losses due to the english pound to us dollar conversion of labcaire 
foreign exchange rates approximately of the company s revenues in fiscal were received in british pounds 
to the extent that the company s revenues are generated in british pounds  its operating results are translated for reporting purposes into us dollars using weighted average rates of and for the fiscal year ended june  and  respectively 
a strengthening of the british pound  in relation to the us dollar  will have the effect of increasing reported revenues and profits  while a weakening of the british pound will have the opposite effect 
since the company s operations in england generally sets prices and bids for contracts in british pounds  a strengthening of the british pound  while increasing the value of its uk assets  might place the company at a pricing disadvantage in bidding for work from manufacturers based overseas 
the company collects its receivables predominately in the currency of the country the subsidiary resides in 
misonix  ltd 
invoices certain customers in euros and as a result there is an exchange rate exposure between the british pound and the euro 
the company has not engaged in foreign currency hedging transactions  which include forward exchange agreements 

